192 related articles for article (PubMed ID: 28803825)
1. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics of vascular adverse events and significance of peripheral artery disease as a risk factor in chronic myeloid leukemia patients treated with nilotinib].
Sumi M; Sato K; Uematsu N; Kawaguchi H; Shishido T; Kaiume H; Takeda W; Kirihara T; Ueki T; Hiroshima Y; Ueno M; Ichikawa N; Urasawa N; Kobayashi H
Rinsho Ketsueki; 2018; 59(2):137-144. PubMed ID: 29515064
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Assunção PM; Lana TP; Delamain MT; Duarte GO; Zulli R; Lorand-Metze I; de Souza CA; de Paula EV; Barbosa Pagnano KB
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):162-166. PubMed ID: 30660512
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
[TBL] [Abstract][Full Text] [Related]
5. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
6. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.
Breccia M; Molica M; Zacheo I; Serrao A; Alimena G
Ann Hematol; 2015 Mar; 94(3):393-7. PubMed ID: 25304102
[TBL] [Abstract][Full Text] [Related]
7. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
10. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
12. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
[TBL] [Abstract][Full Text] [Related]
13. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
15. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
16. Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.
Martino B; Mammì C; Labate C; Rodi S; Ielo D; Priolo M; Postorino M; Tripepi G; Ronco F; Laganà C; Musolino C; Greco M; La Nasa G; Caocci G
Exp Hematol; 2017 Nov; 55():71-75. PubMed ID: 28757432
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
18. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
[TBL] [Abstract][Full Text] [Related]
19. Progressive cardiovascular disease in a patient under treatment with nilotinib.
Roa-Chamorro R; Torres-Quintero L; García de Los Ríos C; Puerta-Puerta JM; González-Bustos P; Mediavilla-García JD
Clin Investig Arterioscler; 2020; 32(2):66-69. PubMed ID: 31280877
[TBL] [Abstract][Full Text] [Related]
20. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Kim TD; Rea D; Schwarz M; Grille P; Nicolini FE; Rosti G; Levato L; Giles FJ; Dombret H; Mirault T; Labussière H; Lindhorst R; Haverkamp W; Buschmann I; Dörken B; le Coutre PD
Leukemia; 2013 Jun; 27(6):1316-21. PubMed ID: 23459449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
